Literature DB >> 16557793

Modifying effect of colicin on experimental Shigella keratoconjunctivitis.

A J Streelman1, I S Snyder, E W Six.   

Abstract

The ability of colicinogenic bacteria and colicin to inhibit Shigella sonnei during the course of infection was studied. Infection of the guinea pig conjunctivae was used as the experimental model. In S. sonnei-infected guinea pig conjunctivae which were treated with a colicinogenic strain of Escherichia coli or with colicin, the number of S. sonnei cells was lower than in animals infected with S. sonnei but not treated. The decrease in the number of pathogenic organisms was associated with absence of disease. A noncolicinogenic strain of E. coli had no effect on production of disease in infected animals. Treatment with a colicinogenic strain of E. coli or colicin did not affect the production of disease or the numbers of organisms in an animal infected with a colicin-resistant strain of S. sonnei.

Entities:  

Year:  1970        PMID: 16557793      PMCID: PMC415957          DOI: 10.1128/iai.2.1.15-23.1970

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  In vivo and in vitro antagonism of intestinal bacteria against Shigella flexneri. I. Correlation between various tests.

Authors:  D J HENTGES; R FRETER
Journal:  J Infect Dis       Date:  1962 Jan-Feb       Impact factor: 5.226

2.  The use of the guinea-pig conjunctivae as an experimental model for the study of virulence of Shigella organisms.

Authors:  D C MACKEL; L F LANGLEY; L A VENICE
Journal:  Am J Hyg       Date:  1961-03

3.  Colicins and colicinogenic factors.

Authors:  P FREDERICQ
Journal:  Symp Soc Exp Biol       Date:  1958

4.  Colicins.

Authors:  P FREDERICQ
Journal:  Annu Rev Microbiol       Date:  1957       Impact factor: 15.500

5.  Inactivation of bacteriocins in the intestinal canal and oral cavity.

Authors:  J Kelstrup; R J Gibbons
Journal:  J Bacteriol       Date:  1969-09       Impact factor: 3.490

6.  Interaction in the germfree mouse intestine of colicinogenic and colicin-sensitive microorganisms.

Authors:  N S Ikari; D M Kenton; V M Young
Journal:  Proc Soc Exp Biol Med       Date:  1969-04

7.  The influence of bacteriocins on resistance to infection by gram-negative bacteria. II. Colicin action, transfer of colicinogeny, and transfer of antibiotic resistance in urinary infections.

Authors:  A I Braude; J S Siemienski
Journal:  J Clin Invest       Date:  1968-08       Impact factor: 14.808

8.  Inhibition of Shigella flexneri by the normal intestinal flora. II. Mechanisms of inhibition by coliform organisms.

Authors:  D J Hentges
Journal:  J Bacteriol       Date:  1969-02       Impact factor: 3.490

9.  Colicine K. II. The preparation and properties of a substance having colicine K activity.

Authors:  W F GOEBEL; G T BARRY
Journal:  J Exp Med       Date:  1958-02-01       Impact factor: 14.307

10.  Colicine K. III. The immunological properties of a substance having colicine K activity.

Authors:  T AMANO; W F GOEBEL; E M SMIDTH
Journal:  J Exp Med       Date:  1958-11-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Colicinogeny and related phenomena.

Authors:  K G Hardy
Journal:  Bacteriol Rev       Date:  1975-12

2.  Haemocin, the bacteriocin produced by Haemophilus influenzae: species distribution and role in colonization.

Authors:  J J LiPuma; H Richman; T L Stull
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  The Clostridium difficile cpr locus is regulated by a noncontiguous two-component system in response to type A and B lantibiotics.

Authors:  Jose M Suárez; Adrianne N Edwards; Shonna M McBride
Journal:  J Bacteriol       Date:  2013-03-29       Impact factor: 3.490

4.  Characterization of Lactobacillus sp. strain 100-37 from the murine gastrointestinal tract: ecology, plasmid content, and antagonistic activity toward Clostridium ramosum H1.

Authors:  E L McCormick; D C Savage
Journal:  Appl Environ Microbiol       Date:  1983-11       Impact factor: 4.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.